{"id":7362,"date":"2011-04-03T10:16:29","date_gmt":"2011-04-03T14:16:29","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=7362"},"modified":"2011-07-19T17:44:29","modified_gmt":"2011-07-19T21:44:29","slug":"partner-a-tavi-noninferior-to-surgery-but-stroke-might-be-a-problem","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/04\/03\/partner-a-tavi-noninferior-to-surgery-but-stroke-might-be-a-problem\/","title":{"rendered":"PARTNER A: TAVI Noninferior to Surgery, but Stroke Might Be a Problem"},"content":{"rendered":"<p>Here are the main results of the much anticipated PARTNER A trial  comparing transcatheter aortic valve implantation (TAVI) versus surgery  for  aortic valve replacement (AVR). They were presented this morning in New Orleans at the ACC.<\/p>\n<p>Some 699 high-risk older patients with severe aortic  stenosis were  randomized to either TAVI or AVR.\u00a0 The primary endpoint, all-cause  mortality at 1 year, was 24.2% in the TAVI group and 26.8%\u00a0 in the AVR group (HR 0.93, CI 0.71-1.22, p=0.62), thereby meeting the prespecified  margin for noninferiority. Thirty-day mortality was 3.4% and 6.5%, respectively (p=0.07).<\/p>\n<p>The rate of major stroke at 1 year was 5.1% for TAVI versus  2.4% for AVR (p=0.07). For all strokes, the difference achieved  statistical significance: 8.3% versus 4.3% (p=0.04). There were no  significant differences at either 30 days or 1 year in cardiac  mortality, rehospitalization, MI, or acute renal injury requiring renal  replacement therapy.<\/p>\n<p>Major vascular complications occurred more frequently with TAVI, both at 30 days (11% versus 3.2%, p&lt;0.01) and at 1 year (11.3%  versus 3.5%, p&lt;0.01). Major bleeding, on the other hand, occurred  more often with AVR, both at 30 days (9.3% versus 19.5%,  p&lt;0.01) and at 1 year (14.7% versus 25.7%, p&lt;0.01).<\/p>\n<p>New AF occurred more frequently in the surgery group: 12.1% versus  17.1% at 1 year (p=0.07).<\/p>\n<p>The rate of all-cause mortality or stroke was 26.5% for TAVI versus  28% for AVR (p=0.70).<\/p>\n<p>The authors conclude: \u201cBoth [TAVI] and AVR were associated with important\u000b but  different peri-procedural hazards: Major strokes at 30 days and one  \u000byear and major vascular complications were more frequent with [TAVI.]  Major bleeding and new onset atrial fibrillation were more frequent with  AVR.  [TAVI] and AVR are both acceptable therapies in these \u000b high-risk  patients; differing peri-procedural hazards\u000b may impact case-based  decision-making.\u201d<\/p>\n<p><em>View <strong>Rick Lange&#8217;s<\/strong> Interventional Cardiology blog on the PARTNER A trial <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/tavi-partner-or-blind-date\/\">here<\/a>, and for more of our ACC.11 coverage of late-breaking clinical trials,  interviews with the authors of the most important research, and blogs  from our fellows on the most interesting presentations at the meeting,  check out our <a href=\"..\/acc-11-cardioexchange-coverage-roundup\/\">Coverage Roundup<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here are the main results of the much anticipated PARTNER A trial comparing transcatheter aortic valve implantation (TAVI) versus surgery for aortic valve replacement (AVR). They were presented this morning in New Orleans at the ACC. Some 699 high-risk older patients with severe aortic stenosis were randomized to either TAVI or AVR.\u00a0 The primary endpoint, [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20,9],"tags":[424,423,770],"class_list":["post-7362","post","type-post","status-publish","format-standard","hentry","category-cardiac-surgery","category-interventional-cardiology","tag-aortic-valve-replacement","tag-tavi","tag-tavr"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=7362"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7362\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=7362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=7362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=7362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}